We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
House members are growing impatient with the FDA over a lack of guidance on biosimilars, with several venting their frustrations during a hearing last month. Read More
The Senate HELP Committee’s second of three markups is scheduled for March 9 to examine several pieces of legislation as part of the Senate’s piecemeal version of the House’s 21st Century Cures Act. Read More
Johnson & Johnson unit Janssen and AbbVie got the red light from the UK’s National Institute for Health and Care Excellence, which did not recommend the drug giants’ chronic lymphocytic leukemia drug Imbruvica. Read More